GelTex Incorporated Company Profile

00:00 EDT 2nd July 2016 | BioPortfolio

We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis patients.

In addition, WelCholTM brand colesevelam hydrochloride was granted marketing approval by the FDA in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood cholesterol levels.


153 Second Avenue
United States of America


Phone: 781 290 5888
Fax: 781 290 5890

News Articles [6 Associated News Articles listed on BioPortfolio]

OncoSec Medical Incorporated's CEO Punit Dhillon Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - June 02, 2016) - Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. Onc...


CATERPILLAR INC. FILES FORM 8-K PEORIA, Illinois, April 22, 2016 - Caterpillar Inc. (NYSE: CAT/Euronext: CATR) informs its stockholders that today Caterpillar Inc. furnished a Form 8-K to the SEC ...

CATERPILLAR INCORPORATED - Caterpillar to Participate in Wells Fargo Conference

Caterpillar to Participate in the Wells Fargo Securities Industrial and Construction Conference on May 11; Webcast Available PEORIA, Ill., May 9, 2016 -- Caterpillar Inc. (NYSE: CAT) Group Preside...


Caterpillar Inc. to Announce Full-Year and Fourth-Quarter 2015 Financial Results on January 28 PEORIA, Ill., Jan. 14, 2016 -- Caterpillar Inc. (NYSE: CAT) will release full-year and fourth-quarter...

Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 01/21/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and prov...

PnuVax to acquire inactivated yellow fever vaccine intellectual property from GE Healthcare

Companies to optimize manufacturing process using GE FlexFactory CHALFONT ST. GILES, UK and KINGSTON, ONTARIO, CANADA – 8 June 2016 – PnuVax Incorporated (PnuVax), a vaccine and biopha...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

GelTex Pharmaceuticals Incorporated

GelTex Pharmaceuticals, Inc. is developing non-absorbed, polymer-based pharmaceuticals that selectively bind to andeliminate target substances from the intestinal tract. In October 1998, the Company r...

GelTex Incorporated

We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s ...

More Information about "GelTex Incorporated" on BioPortfolio

We have published hundreds of GelTex Incorporated news stories on BioPortfolio along with dozens of GelTex Incorporated Clinical Trials and PubMed Articles about GelTex Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GelTex Incorporated Companies in our database. You can also find out about relevant GelTex Incorporated Drugs and Medications on this site too.

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record